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22700 diabetic patients in Madrid was used to estimate transition probabilities in 
the model. Time horizon was 10 years. Prices were taken from the health care tariffs 
published by the Regional Health Service in Madrid and from Spanish literature. They 
were updated to 2013 price levels and adjusted to subsequent years by a 3% infla-
tion rate. We used the perspective of the Regional Health Service in Madrid (public 
payer). Results: The model included an acute event and 3 health states. The increase 
in total costs in 10 years was € 1,328 per DM patient (133 € per year). In patients 
with hypertension the costs increased by 1,519€ in 10 years (152 € ); whereas the 
total increase in costs in patients with obesity was 1,535 € (153 € ). ConClusions: 
IS has a relevant impact on the costs of management of DM. Hypertension and 
obesity increase these costs even further. Prevention of DM complications and an 
adequate control of risk factors can lead to cost savings for the management of DM. 
Understanding future costs of DM might be valuable for economic evaluations.
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BACkgRound: High prevalence and chronic complications are key determinants 
of management costs of Diabetes Mellitus (DM). Given that DM affects more than 4 
million people in Spain, the costs associated with this disease require an efficient 
management. Cardiovascular diseases are complications associated with DM with 
a major impact in health care budgets. oBjeCtives: Develop a model to predict 
future costs of DM in Spain. Estimate the increase in health care costs in DM patients 
associated with potential cardiovascular diseases. We used the perspective of the 
Regional Health Service in Madrid (public payer). Methods: Foro Gerendia is an 
initiative constituted by health care professional, experts in DM management. A 
Markov model for DM was developed based on the opinion of Foro Gerendia and on 
previous works in this area. A 5-year primary care data registry of 22700 diabetic 
patients in Madrid was used to estimate transition probabilities in the model. Time 
horizon was 10 years. Prices were taken from the health care tariffs published by the 
Regional Health Service in Madrid and from Spanish literature. They were updated to 
2013 price levels and adjusted to subsequent years by a 3% inflation rate. Results: 
Cardiovascular complications included in the model were ischemic heart diseases 
(acute myocardial infarction and angina) and heart failure with a total of 5 health 
states. The estimated increase in costs was € 1,080 per patient in 10 years (€ 108 
per year). Considering an 8% prevalence of DM in Madrid, the increase in costs of 
DM due to cardiovascular diseases would be € 52 million per year. ConClusions: 
Cardiovascular diseases in DM patients have a relevant impact on health care 
expenditure. Prevention of cardiovascular complications can lead to significant 
cost savings for the management of DM. Understanding future costs of DM might 
be valuable in terms of budget allocation and economic evaluation.
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oBjeCtives: Hypercholesterolemia is a risk factor for ciculatory diseases. This study 
estimates the impact of hypercholesterolemia on populations’ health levels and its 
economic impact in Portugal. Methods: The impact on health status is measured 
by the loss of life years adjusted for disability (DALYs - Disability Adjusted Life Years). 
The economic impact analysis includes two components. The first estimates the 
direct costs generated by hypercholesterolemia including consumption of health 
care, social support, and other associated costs (e. g. transport). The second esti-
mates indirect costs, those related to the losses of productivity. The disease burden 
and the costs of illness attributable to hypercholesterolemia include also the com-
plications attributable to this risk factor, namely ischemic stroke and ischemic heart 
disease. In order to estimate the attributable fractions to hypercholesterolemia (total 
cholesterol ≥ 200mg/dL or statin use) of the diseases considered, a microsimulation 
approach was employed by using Framingham equations on the national database 
(VALSIM). In a counterfactual scenario hypercholesterolemia was eliminated from 
these observations and the resulting proportional change in the probability of CV 
events was taken as the hypercholesterolemia attributable fractions. These frac-
tions were used to estimate the contribution of hypercholesterolemia to the burden 
and the annual costs of the aforementioned circulatory diseases. Results: 1,689 
deaths can be attributed to hypercholesterolemia, which corresponds to 1.6% of the 
total deaths in Portugal in 2010. The DALYs resulting from disability and premature 
deaths caused by hypercholesterolemia in 2010 totaled 12,174. The estimated direct 
cost attributable to hypercholesterolemia in 2013 prices is € 320 million (€ 32 million 
for in-patient care and € 288 million for ambulatory care). Indirect costs generated by 
disability attributable to hypercholesterolemia add up to € 198 million. The overall 
costs of disease are therefore estimated at € 518 million, about 0.3% of Portuguese 
GDP. ConClusions: In Portugal, we observed substantial burden and costs associ-
ated with Hypercholesterolemia.
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was significantly reduced versus CG (€ 6,798 vs € 6,954, p< 0.001). PAP recipients had 
a significantly lower 3-year mortality rate versus CG (7.2% vs 10.9%, p< 0.008; rela-
tive risk reduction 33.8%). ConClusions: SA patients with T2DM treated with PAP 
showed significantly reduced mortality and morbidity. Total COI was higher in PAP 
recipients versus CG in the first two years of follow-up, but during year 3 COI was 
significantly lower in the PAP group versus CG. In addition to the known advantages 
of PAP therapy in SA patients with T2DM (e. g. improved glycaemic control), PAP 
therapy may be beneficial from an economic perspective.
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oBjeCtives: To determine differences in total health care expenditures among 
general diabetics and newly diagnosed diabetics before and after HbA1c was 
implemented as the standard diagnostic factor. Methods: Medical Expenditure 
Panel Survey-Household component 2009 and 2011 databases were used. Annual 
health care expenditures formed the dependent variable. Demographic factors, 
comorbidities, prescription drug costs, medical events and utilization variables for 
health care services like visits to office-based, outpatient and inpatient facilities, 
emergency rooms, home health care for 2009 and 2011 formed the independent 
variables. Patients diagnosed within the 2009 and 2011 years, were categorized into 
a dichotomous new diagnosis variable. General linear regression was conducted 
to compare predictors of total diabetes health care expenditures in 2009 and 
2011. Results: The mean total health care expenditure decreased in 2011 com-
pared to 2009 among general diabetics {$10,901 (95%CI= $9,013-$11,836) vs $11,458 
(95%CI= $10,715-$12,201)} and the newly diagnosed ones {$9,462 (95%CI= $6201-
$12,721) vs $8,429 (95%CI= $6793- $10,064)}. Among general diabetics in 2009, total 
expenditures showed significant relationships with prescription drugs, emergency 
room, home health care, outpatient facility and physician services expenses (all 
values p< 0.0001). The 2011 model was similar, but included associations between 
office-based provider visits (p< 0.0001) and previous incidences of heart attacks 
(p= 0.008). In 2009, among newly diagnosed patients, total expenditures were 
significantly associated with home health facilities expenditure (p< 0.0001) as 
opposed to no association in 2011. In both years, prescription medication, emer-
gency room and hospital inpatient facilities expenses contributed to spending. 
Visits to office-based and outpatient department providers, number of home-
health provider days (all values p< 0.0001) and hospital discharges (p= 0.0011) 
impacted total expenditures in 2009 and 2011 respectively. ConClusions: Due 
to the many variables significantly affecting diabetes health expenditures, reduc-
tion in costs could not be solely attributed to the implementation of the HbA1c 
diagnostic criteria. Further research on cost-effectiveness of the HbA1c factor is 
warranted to establish any possible association.
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oBjeCtives: The aim of this study was to assess the direct costs of ambulatory 
treatment associated with types 1 and 2 diabetes mellitus (DM) from the public 
payer perspective in Poland, and to explore the relative contribution of different cost 
components in the total direct cost of DM. Methods: The estimates were based 
on reimbursement data from the years 2012 and 2013 provided by the public payer 
in Poland. Reimbursement costs of insulin, oral anti-diabetes drugs and monitoring 
strips were taken into account. Costs were presented in Polish zloty (PLN). Results: 
Total reimbursement costs for the public payer of anti-diabetes treatment were 1.3 
billion PLN in 2012 and 1.5 billion PLN in 2013, representing 19% and 21% of the 
total Polish reimbursement expenditures in 2012 and 2013, respectively. The highest 
component of anti-diabetes treatment costs was monitoring strips (645 million PLN 
in 2012 and 793 million PLN in 2013, 49% and 52%, respectively). Insulin costs (518 
million PLN in 2012 and 583 million PLN in 2013) and anti-diabetes oral drug costs 
(144 million PLN in 2012 and 155 million PLN in 2013) constitute 38-40% and 10-11% 
of total reimbursement costs, respectively. Regarding insulin, human insulin had a 
larger share of the costs (60-62%) than insulin analogs (38-40%). Premixed human 
insulin (65-66% reimbursement costs) and premixed insulin analogs (47-52% reim-
bursement costs) represent the largest share of the reimbursement costs of human 
insulin and insulin analogs, respectively. Reimbursement costs of biguanides and 
sulphonylureas represent 49-54% and 40-44% of total reimbursement costs of oral 
anti-diabetes drugs, respectively. ConClusions: Total direct costs of diabetes mel-
litus treatment constitute a major part of reimbursement expenditures in Poland 
and are still growing. The main cost driver was reimbursement of monitoring strips, 
and the costs of insulin reimbursement were slightly lower.
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BACkgRound: Diabetes (DM) has a relevant impact on health care budgets mainly 
due to its high prevalence and its chronic and acute complications. Isquemic stroke 
(IS) is one of the macrovascular complications associated with DM and its incidence 
increases with the presence of some risk factors such as hypertension and obe-
sity. oBjeCtives: Develop a model to predict future costs of DM in Spain. Estimate the 
increase in health care costs associated with potential IS in DM patients. Methods: 
Foro Gerendia is an initiative constituted by health care professional, experts in DM 
management. A Markov model for DM was developed based on the opinion of Foro 
Gerendia and on previous works in this area. A 5-year primary care data registry of 
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oBjeCtives: To estimate medical expenditure for people with diabetes covered 
by Urban Employee Basic Medical Insurance (UEBMI) in Fujian. Methods: Claims 
data were extracted from UEBMIF database during 2012.1. 1 to 2012.12.31. People 
with diabetes were identified by keyword – diabetes. To estimate expenditures, we 
used Sum_All Medical method. Descriptive analyses were conducted by using EXCEL 
2010. Results: In 2012, one of the Fujian UEBMI database recorded claims data of 
240079 patients, including 5953 with diabetes (2.48%), among which 68.81% were male 
and 91.03% were age over 50. The number of General Outpatient (GO)/Catastrophic 
Outpatient (CO)/inpatient with diabetes was 5196/4964/2325. GO/CO with diabetes 
visited physicians averagely 24.13/46.02 times, almost 60% of the visits happened in 
tertiary hospitals. People with diabetes each used inpatient services 1.70 times; the 
mean number of LOS was 16.52 days. Total Direct Medical Expenditure for people with 
Diabetes (TDMED) was CNY 132 million (16.33% of total direct medical expenditure); 
out-of-pocket spending accounted for 27.20%. GO/CO/inpatient medical expenditures 
were CNY 3824.16/7960.88/31365.25 per person and CNY 158.49/172.97/18396.62 per 
visit. Expenses for medicine was CNY 89 million (67.01% of TDMED), only CNY 17 mil-
lion (13.03% of TDMED) was spent on anti-glycaemic medicine. 94.56% of people with 
diabetes took prescribed anti-glycaemic medicine, including OAD (88.34%), insulin 
(41.21%) and traditional Chinese medicine (23.13%). For CO, 47.26% of the visits were 
due to diabetes and the medical expenditure accounted for 43.40%. Among hospi-
talized people with diabetes, only 10.68% of their primary diagnoses were diabetes. 
Inpatient with diabetes whose primary diagnoses were diabetes consumed less health 
care resources (average LOS/medical expenditure per person/medical expenditure 
per visit) than those whose primary diagnoses were diabetic complications or other 
diseases (15.47days/CNY 14567.57/CNY 12481.90 vs. 16.65days/CNY 27666.67/CNY 
19161.66). ConClusions: Diabetes, as one of the major chronic diseases, consumed 
a large amount of medical resources in Fujian. Majority of direct medical expenditure 
were spent on treating diabetic complications and other diseases.
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oBjeCtives: The aim of this study was to assess the indirect costs associated with 
types 1 and 2 diabetes mellitus (DM) from the perspective of the Social Insurance 
Institution (ZUS) in Poland. Methods: The estimates were based on data from the 
year 2012 concerning absence from work due to the illness (sick leave) the amount 
of short term disability, the sufferers of which claim rehabilitation benefit, and the 
amount of permanent (or long term) disability, the sufferers of which claim dis-
ability pension. Costs were presented in Polish zloty (PLN). Results: Total indirect 
costs of DM types 1 and type 2 in the year 2012 in Poland were 59 013 912 PLN and 
66 597 701 PLN, respectively. The highest component of indirect costs of DM type 1 
was sick leave (61%). Long and short term disability costs constitute 28% and 11% 
of total indirect costs of DM type 1, respectively. A slightly different situation was 
reported in the case of type 2 diabetes: long term disability costs were only 1% of 
total indirect costs, and short term disability had a slightly larger part of indirect 
costs (less than 5%). The highest component of indirect costs of DM type 2 was sick 
leave (95%). One sick leave of a person with types 1 or 2 diabetes generated a cost 
of lost productivity equal to 1 771 PLN or 1 585 PLN, respectively. The cost of dis-
ability pension per one person was higher than rehabilitation benefit, and equalled 
41 398 PLN compared with 17 249 PLN (the average value of one short and long 
term benefit payment was the same for both types of diabetes). ConClusions: 
DM in Poland generated high indirect costs. The main component was sick leave; 
rehabilitation benefit and disability pension generated much lower costs for Social 
Insurance Institution.
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oBjeCtives: Type 2 Diabetes Mellitus (T2DM) is a worldwide prevalent chronic 
disease, related to high morbidity and mortality, and to significant socioeconomic 
costs. However, the magnitude of cost varies significantly among empirical studies. 
The objective of this literature review is to identify the main drivers that influ-
ence the costs of T2DM. Methods: We searched relevant databases for studies 
estimating T2DM costs, published in English and Spanish in the USA and Europe 
(1995-2014). Search terms included “diabetes”, “costs”, “burden”, and “economic 
impact”. No exclusion was made based on study design. Cost drivers and differences 
in methodologies across studies were identified. Results: A total of 25 papers 
were included out of 618 relevant titles identified. Costing methodologies and cost 
drivers vary significantly causing important variations in results. The main differ-
ence in methodology refers to estimating T2DM costs versus the costs of people 
living with T2DM, which include all direct sanitary costs -whether directly related 
to T2DM or not- and may increase total costs by up to 74%. Direct sanitary costs 
range between 40% and 75% of total costs depending partially on whether produc-
tivity losses and caregiving are considered. The relative weight of hospitalizations 
range between 20% and 60% of sanitary costs depending on the categories included. 
Pharmacologic costs range between 13% and 46%, which include antidiabetic drugs 
and treatments for complications derived from poor control. Optimal glycemic con-
trol reduces costs but is not always considered in the studies. Microvascular and/
or macrovascular complications and hypoglycemic events increase total cost per 
patient. ConClusions: Differences in costing methodology, the type of cost cat-
egories included in the analysis and the source of data greatly influence the results 
of the studies and impede reaching accurate conclusions regarding the cost of T2DM. 
Designing standardized costing methodology guidelines would help future studies 
estimate the real burden of T2DM.
oBjeCtives: To determine the clinical (compliance, metabolic control, hypoglycae-
mia and cardiovascular events [CVE]) and economic (resources and costs) impact 
of metformin in combination with dipeptidyl peptidase-4 inhibitors (DPP4-I) or 
sulfonylureas in patients with type 2 diabetes. Methods: Design: Multicentre, 
observational retrospective study. Patients aged ≥ 30 years under treatment with 
metformin who initiated a second oral antidiabetic treatment in 2008-2009 were 
evaluated. Two study groups were established: a) metformin + DPP4-I, b) met-
formin + sulfonylureas. Main measures: comorbidity, metabolic control (HbA1c < 
7%), compliance and complications (hypoglycaemia, CVE). Patients were followed 
for 2 years. The cost model considered direct (primary/specialised care) and indi-
rect (productivity) health care costs. Statistical analysis: logistic regression models 
and ANCOVA, p < 0.05. Results: We recruited 1,405 patients (men age 67.1 years, 
56.2% male) of whom 37% initiated a second treatment with DPP4-I and 63% with 
sulfonylureas. At 2 years follow-up, patients treated with DPP4-I showed better 
compliance (70.3% vs 60.6%), better metabolic control (64.3% vs 60.6%), and a lower 
proportion of hypoglycaemia (13.9% vs 40.4%) (p < 0.05). The mean unit costs of the 
total adjusted costs were € 2,341 vs € 2,512, respectively; p = 0.038. Rates of CVE 
and renal failure were 3.7% vs 6.4%; p = 0.027. Vildagliptin was the most commonly 
used DPP4-I. ConClusions: Sulfonylureas were the most frequently used drugs 
for the treatment of diabetes. Patients treated with DPP4-I had better compliance 
and control of diabetes, with lower rates of hypoglycaemia and CVE, resulting in 
reduced health care costs.
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oBjeCtives: To estimate the impact of diabetic complications on immediate and 
long-term direct medical costs in Hong Kong. Methods: A retrospective cohort 
study was conducted among 137,634 diabetic subjects from a territory-wide admin-
istrative database over six years (2008-2013). The trends of annual direct medi-
cal costs were analyzed by three groups: group 1) subjects without complications 
over study period; group 2) subjects with existing complications at baseline; and 
group 3) subjects developing new complications during follow-up. We employed 
panel data regression to investigate the impact of each diabetic complication on 
direct medical costs in the event year and subsequent years, adjusting for age and 
Charlson Comorbidity Score. Results: We found 10,322 subjects with existing 
diabetic complications at baseline (January 1st, 2009), and 14,349 newly developed 
diabetic complications over 5 years. The annual direct medical costs increased from 
$US4,629 to $US15,585 in the new complications group, which is substantially higher 
than the modest rise in the no complication group (from $US1,157 to $US1,984). The 
annual direct medical cost of baseline case was $US1,062 (62 year-old, no compli-
cation, Charlson Comorbidity Score= 0). After adjusting for age and comorbidity, 
compared to the baseline case, the multipliers of annual direct medical costs in 
the event year were: acute myocardial infarction (AMI) 10.61; other ischemic heart 
disease (IHD) 3.67; congestive heart failure (CHF) 8.46; stroke 10.17; sight threaten-
ing diabetic retinopathy (STDR) 3.41; blindness 2.78; end stage renal disease (ESRD) 
12.16; peripheral vascular disease (PVD) 3.00; amputation: 3.48. The multipliers in 
subsequent years were: AMI 1.45; other IHD 1.32; CHF 1.86; stroke 1.37; STDR 2.16; 
blind 1.32; ESRD 1.86; PVD 1.42; amputation 1.32. ConClusions:  There were wide 
variations in direct medical cost in event year and subsequent years across differ-
ent major complications. These data would be useful for economic evaluations of 
diabetes prevention or treatment programs.
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oBjeCtives: This study aimed to analyze the direct medical cost of diabetes related 
micro- and macrovascular complications in Korean people with diabetes melli-
tus. Methods: Using the Health Insurance Review & Assessment Service-National 
Patients Sample (about 1.3 million patients), which was a stratified sampling from 
the entire population (about 46 million persons) under the Korean national health 
security system (2011), estimation of direct medical cost complication for patients 
who have diabetes related chronic complications were performed. We used the 
6th revision of Korean Standard Classification of Diseases (KCD-6) which had been 
developed with the reference of the 10th version of International Classification (ICD-
10). All statistical analyses were performed using the Statistical Analysis System 
(SAS, version 9.3). Results: The mean age of the subjects was 61.4 years, 52.1% were 
male and 47.9% were female. Of the 91,463 patients with DM, 20,584 patients (22%) 
had at least one microvascular or macrovascular complication, 70,879 patients (78%) 
had no complication. The average annual direct medical cost in patients who had 
no complications was 351,660 won in 2011. The average annual direct medical cost 
in patients who had microvascular complications such as retinopathy, nephropathy, 
neuropathy was 506,160 won, 1.4 times higher than without DM complications, who 
had macrovascular complications such as MI, CVA, ESRD was 1,362,928 won, 3.8 
times higher than without DM complications. ConClusions: Diabetic complica-
tions have a substantial impact on the direct medical costs of DM patients. As the 
number of people with diabetes continues to rise, early detection of the disease and 
implementation of timely and appropriate therapeutic strategies could decrease 
the burden of diabetes chronic complications and also huge related expenditures.
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